Partners and Integration HUREL is now part of Visikol, signaling a potential cross-sell of Visikol’s imaging, GLP services, and BBB permeability assays to HUREL customers, while leveraging Visikol’s expanded tissue imaging capabilities.

BBB Expertise Visikol’s ongoing focus on blood brain barrier assays and models presents a clear opportunity to sell advanced BBB permeability testing, transport mechanism studies, and drug delivery research to neuropharmacology and CNS therapeutic customers.

Imaging Growth Recent launches of multiplex tissue imaging, Imaging Mass Cytometry, and advanced tissue slice models indicate strong capacity to offer high-content analysis, biomarker discovery, and GLP-compliant imaging services to pharma, biotech, and academic clients.

Data and Outreach A tech stack centered on Google Ads, HubSpot, LinkedIn tools, and email services suggests robust digital marketing and sales enablement potential; leverage these channels to target CROs, academic labs, and biotech groups with tailored value propositions.

Financial Signals With revenue in the low to mid single digits and a funding runway of several million, there is appetite for strategic partnerships, joint ventures, or contract research collaborations to accelerate service adoption and scale capabilities.